Effect of Sulodexide on Albuminuria, NAG Excretion and Glomerular Filtration Response to Dopamine in Diabetic Patients
- 1 January 2006
- journal article
- research article
- Published by S. Karger AG in American Journal of Nephrology
- Vol. 26 (6), 621-628
- https://doi.org/10.1159/000098195
Abstract
Background: Albuminuria is the best and most readily available marker for glomerular damage and progressive renal function loss in patients with diabetic nephropathy. Recently, administration of the oral glycosaminoglycan sulodexide (a mixture of 80% fast-moving heparin and 20% dermatan sulphate) was shown to effectively decrease albumin excretion rate in diabetics with nephropathy. Aims: To evaluate whether the hypoalbuminuric effect of sulodexide is associated with improvement of the renal vascular or tubule function. Methods: Forty-five type 1 diabetic patients, affected by diabetic nephropathy with albuminuria for at least 5 years, were randomly allocated to sulodexide or untreated. Those allocated to sulodexide were given 100 mg of sulodexide daily for 120 days. Renal vascular function (DIR) and N-acetyl-β-D-glucosaminidase (NAG) excretion were estimated before and at the end of the study, the former in thesulodexide group only. DIR was measured as two Crcl lasting 120 min (before and during 2 µg/kg b.w. i.v. dopamine). Results: The analysis of trends during the study demonstrated a marked reduction of albuminuria in the sulodexide group (from 126.1 ± 15.41 to 93.6 ± 13.7 mg/day). DIR rose from 13.2 ± 2.1% to 15.44 ± 1.9% (relative increase: +16.9%), and NAG excretion showed a decreasing trend decreased in the sulodexide group only (from 5.1 ± 0.62 to 4.7 ± 0.40 U/gcreat). Conclusion: The findings presented in this study indicate for the first time that orally available sulodexide may favorably affect the renal vascular function in type 1 diabetic patients with nephropathy and microalbuminuria. The effect of sulodexide on NAG is strongly influenced by the baseline NAG values, with a significant NAG reduction in the patients with the highest baseline NAG values.Keywords
This publication has 22 references indexed in Scilit:
- Effect of 12-Month Therapy with Omega–3 Polyunsaturated Acids on Glomerular Filtration Response to Dopamine in IgA NephropathyAmerican Journal of Nephrology, 2004
- Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients With NephropathyCirculation, 2004
- Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAALKidney International, 2004
- Transforming growth factor-beta1 reduces megalin- and cubilin-mediated endocytosis of albumin in proximal-tubule-derived opossum kidney cellsThe Journal of Physiology, 2003
- Urinary N-acetyl-beta-glucosaminidase excretion is a marker of tubular cell dysfunction and a predictor of outcome in primary glomerulonephritisNephrology Dialysis Transplantation, 2002
- Subject Index Vol. 11, 2000Dementia and Geriatric Cognitive Disorders, 2000
- Glycosaminoglycan therapy for long-term diabetic complications?Diabetologia, 1998
- N-acetyl-beta-D-glucosaminidase urinary excretion as an early indicator of kidney dysfunction in rheumatoid arthritis patients on low-dose methotrexate treatmentRheumatology, 1997
- Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathyKidney International, 1994
- Microalbuminuria as a predictor of clinical diabetic nephropathyKidney International, 1987